Elucida Oncology to Present Preclinical Data on ELU001 at the American Association for Cancer Research Annual Meeting

NEXT STORY
Theratechnologies Announces Two Strategic Hires to Support its Commercial and Pipeline Assets
PREV STORY
Predictmedix Inc. Announces Engagement of Investment Banking Firm Kingswood Capital Markets
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

RespireRx Pharmaceuticals Inc. Announces CEO’s OTC Venture Market Podcast

author_avatar
NASDAQ Market News

Rafael Pharmaceuticals Announces Initiation of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613 (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

500 patients will be evaluated in this study at approximately 87 sites in 12 ...

author_avatar
NASDAQ Market News

Ascendis Pharma A/S Announces Preliminary Six-Month Data from Open-Label Extension of Phase 2 PaTH Forward Trial and Files IND Amendment to Initiate Phase 3 PaTHway Trial of TransCon™ PTH in Adult Hypoparathyroidism

author_avatar
NASDAQ Market News